FDA confronts surge of Chinese biotech firms as they become key industry players

The FDA is currently assessing how to handle the rapid growth of biotech companies from China, which have moved from being economic competitors to important contributors in the pharmaceutical landscape.

Agency officials say the influx of Chinese-developed therapies and technologies presents both regulatory challenges and opportunities to ensure safety and efficacy while maintaining fair competition.

The FDA plans to adapt its review processes and increase collaboration with international partners to keep pace with the evolving global biotech environment.